Using biosimilars could save your patients 20 to 30 percent on their prescriptions. So why not prescribe them? The U.S. biologics and biosimilars market is evolving rapidly, and the benefits for patient access and controlling health care costs will continue to grow over time as more medicines are introduced.
AGA currently has three education programs on biosimilars in AGA University.
Biosimilars in IBD Care: Resources for Effective Patient-Provider Collaboration
This educational program, supported by an independent educational grant from Pfizer, provides four case-based scenarios with accompanying resources to help physicians navigate the clinical implications for the use of biosimilars for inflammatory bowel disease (IBD). The four case scenarios highlight the needs of IBD patients at different points of care. Each case scenario offers 0.75 CME for a total of 3.0 credits. But hurry! The program is set to expire Dec. 31.
Individual links for the case-based scenarios
Biosimilars: How to Make the Switch
This four-part panel series, also supported by an independent education grant from Pfizer, focuses on real-world practical approaches to the adoption of biosimilars and the data available demonstrating the safety and efficacy of biosimilars in different clinical settings. Completion of all four panels offer 2.0 CME.
Individual links for the case-based scenarios
New! AGA Expert Exchange: Biosimilars in GI
AGA’s newest offering, supported by an independent grant from Amgen Inc., is a blended learning approach hosted on AGA’s Twitter account, the AGA Community and AGA University. The program includes four components: a Tweetorial on the basics of biosimilars, a Twitter chat with the experts, an AGA Community Roundtable panel discussion from Dec. 14 through Dec. 21, and an on-demand module, launching in January, with highlights from the tweetorial, chat and panel discussions along with videos and resources on the application of biosimilars in GI.
For even more on biologics and their use in treating IBD, don’t miss the Crohn’s & Colitis Congress®, taking place Jan. 20-22, 2022 in-person in Las Vegas, with a virtual option as well.
